Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUl 14	FSTA enhanced with Japanese patents
NEWS	14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:42:13 ON 20 SEP 2006

```
=> file registry
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:42:25 ON 20 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 SEP 2006  HIGHEST RN 907944-91-6
DICTIONARY FILE UPDATES:  19 SEP 2006  HIGHEST RN 907944-91-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
be available.  Please contact CAS Customer Care
(http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10511535.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 18:42:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       13 TO ITERATE

100.0% PROCESSED       13 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           44 TO      476
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 18:42:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      476 TO ITERATE

100.0% PROCESSED      476 ITERATIONS                               35 ANSWERS
SEARCH TIME: 00.00.01

L3           35 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 18:42:51 ON 20 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Sep 2006  VOL 145 ISS 13
FILE LAST UPDATED: 19 Sep 2006  (20060919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4           10 L3

=> d abs bib hitstr 1-10
```

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I



II



III

AB The invention relates to a preparation of spiro(azabicyclooctane-furoaryl) of formula I (Ar is a heteroaryl), useful as ligands for nicotinic acetylcholine receptors. For instance, spiro(azabicyclooctane-furopyridine) derivative II was prepared via coupling of trimethylstannylspiro(azabicyclooctane-furopyridine) derivative III with furo[3,2-b]pyridine-3-triflate. The invention compds. showed binding affinities (Ki) of less than 1000 nM.
AN 2005:409525 CAPLUS
DN 142:463709
TI A preparation of spiro(azabicyclooctane-furopyridine) derivatives, useful as ligands for nicotinic acetylcholine receptors
IN Phillips, Eifion
PA Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042538	A1	20050512	WO 2004-GB4484	20041021

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004285751	A1	20050512	AU 2004-285751	20041021
CA 2543436	AA	20050512	CA 2004-2543436	20041021
EP 1678183	A1	20060712	EP 2004-768999	20041021

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

PRAI US 2003-512893P	P	20031021	
WO 2004-GB4484	W	20041021	

OS MARPAT 142:463709

IT 851620-36-5P 851620-38-7P 851620-40-1P
851620-41-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro(azabicyclooctane-furopyridine) derivs. useful as ligands for nicotinic acetylcholine receptors)

RN 851620-36-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-furo[3,2-b]pyridin-3-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851620-38-7 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-furo[3,2-c]pyridin-3-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851620-40-1 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-furo[2,3-b]pyridin-3-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851620-41-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-furo[2,3-c]pyridin-3-yl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AB Our objective was to develop an array of α7-selective nicotinic cholinergic receptor (nAChR)-based imaging agents for PET and SPECT. Methods: (2'R)-N-11C-Methyl-N-(phenylmethyl)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]-5'-amine 1 was synthesized by reaction of the corresponding desmethyl precursor with 11C-CO2 and reduction N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-11C-methylsuffanyl-benzamide 2 was synthesized by reduction of the corresponding disulfide precursor and reaction with 11C-iodomethane. N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-125I-iodo-benzamide 3 was synthesized by halogen exchange of the corresponding bromide. (2'R)-5'-(2-125I-iodo-3-furanyl)spiro[1-azabicyclo[2.2.2] octane]-3,2'(3'H)-furo[2,3-b]pyridine 4 was synthesized by the chloramine-T method. Kinetic biodistribution studies were done in male CD-1 mice by tail vein injection of 3.7 MBq (100 μCi) of the 11C-labeled radiotracer or 0.67 MBq (2 μCi) of the 125I-labeled radiotracer followed by brain dissection and tissue counting. Receptor blockade was determined by pretreatment of the mice with an excess of either unlabeled precursor or nicotine. Results: We synthesized 4 radiolabeled, moderate- to high-affinity, α7-nAChR-based ligands. The compds. were a series of quinuclidine derivs. with an inhibition constant (Ki) < 6 nmol/L (33 pmol/L for 4) for α7-nAChR and selectivities of α7/α4β2 subtypes of ≥14,000. All of the compds. were produced in adequate radiochem. yield and specific radioactivity (>74 GBq/μmol [2,000 Ci/mmol]). No site selectivity or receptor blockade was shown for 1 and 2 (0.91 ± 0.05 and 0.14 ± 0.03 %ID/g [percentage injected dose per g] in the hippocampus [target tissue], resp.). Compound 3 showed low hippocampal uptake (0.25 ± 0.05 %ID/g) but prolonged retention within that structure. Pretreatment with nicotine decreased its uptake by up to 50% in the hippocampus. Similar redns. were also observed within the cerebellum (nontarget tissue). Compound 4 showed

hippocampal uptake of 2.41 ± 0.03 %ID/g and target-to-nontarget uptake ratios of up to 2. Pretreatment of animals with unlabeled 4 resulted in a decrease of hippocampal uptake to 60% of its preblockade value without a corresponding decrease in cerebellar uptake. Conclusion: With further structural optimization, selective imaging of α7-nAChR may be possible.

AN 2005:224984 CAPLUS
DN 143:93125
TI Synthesis and biodistribution of radiolabeled α7 nicotinic acetylcholine receptor ligands
AU Pomper, Martin G.; Phillips, Eifion; Fan, Hong; McCarthy, Dennis J.; Keith, Richard A.; Gordon, John C.; Scheffel, Ursula; Dannals, Robert F.; Musachio, John L.
CS Johns Hopkins University, Baltimore, MD, USA
SO Journal of Nuclear Medicine (2005), 46(2), 326-334
CODEN: JNMEAQ; ISSN: 0161-5505
PB Society of Nuclear Medicine
DT Journal
LA English
IT 816462-87-0P
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biodistribution of radiolabeled α7 nicotinic acetylcholine receptor ligands)
RN 816462-87-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[2-(iodo-125I)-3-furanyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 477727-60-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and biodistribution of radiolabeled α7 nicotinic acetylcholine receptor ligands)
RN 477727-60-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AB The present invention relates to radiolabeled compds. particularly 1-azabicyclo [2.2.2]octane compds. (i.e., quinuclidine compds.) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the α7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compds. of the invention, particularly tissues, organs, or tumors which express a7-nicotinic cholinergic receptor to which the compds. of the invention have an affinity.

AN 2005:14173 CAPLUS
DN 142:88902

TI Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor

IN Pomper, Martin G.; Musachio, John L.; Fan, Hong; Dannals, Robert F.; Foss, Catherine; Phillips, Eifion; Gordon, Jack; McCarthy, Dennis; Keith, Richard; Smith, Mark; Heys, Dick; Dorf, Peter
PA Johns Hopkins University, USA

SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000250	A2	20050106	WO 2004-US20530	20040624
	WO 2005000250	A3	20060323		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005129610	A1	20050616	US 2004-877813	20040624
PRAI	US 2003-482108P	P	20030624		

OS MARPAT 142:88902

IT 816462-87-0P
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(imaging agents for α7-nicotinic receptors)

RN 816462-87-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[2-(iodo-125I)-3-furanyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 477727-60-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(imaging agents for α7-nicotinic receptors)
RN 477727-60-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 816462-89-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(imaging agents for α7-nicotinic receptors)
RN 816462-89-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-iodo-3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AB The invention discloses combinations of α7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 CAPLUS
DN 140:229466
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019947	A1	20040311	WO 2003-SE1352	20030901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003256203	A1	20040319	AU 2003-256203	20030901
	EP 1545537	A1	20050629	EP 2003-791540	20030901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505530	T2	20060216	JP 2004-532517	20030901
	US 2005256146	A1	20051117	US 2005-525783	20050228
PRAI	SE 2002-2598	A	20020902		
	WO 2003-SE1352	W	20030901		

IT 220100-24-3 477727-60-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α7-nicotinic receptor agonists and statins in combination for treatment of neurodegenerative diseases)

RN 220100-24-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 477727-60-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked furyl, benzofuryl or isobenzofuryl; substituted with 1, 2 or 3 substituents, or, when a benzofuryl or isobenzofuryl with 0, 1, 2, or 3 substituents, independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n = 0-2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837088 CAPLUS
DN 139:337962
TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087102	A1	20031023	WO 2003-SE613	20030415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2482311	AA	20031023	CA 2003-2482311	20030415
	AU 2003225456	A1	20031027	AU 2003-225456	20030415
	EP 1499618	A1	20050126	EP 2003-746523	20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009343	A	20050215	BR 2003-9343	20030415
	US 2005176745	A1	20050811	US 2003-511535	20030415
	CN 1662541	A	20050831	CN 2003-813895	20030415
	JP 2005533012	T2	20051104	JP 2003-584058	20030415
	NO 2004004996	A	20050118	NO 2004-4996	20041117
PRAI	SE 2002-1186	A	20020418		
	SE 2002-3607	A	20021204		
	WO 2003-SE613	W	20030415		

OS MARPAT 139:337962

IT 616874-03-4P 616874-04-5P 616874-06-7P
616874-07-8P 616874-09-0P 616874-11-4P
616874-13-6P 616874-14-7P 616874-15-8P
616874-16-9P 616874-18-1P 616874-19-2P
616874-20-5P 616874-21-6P 616874-23-8P
616874-24-9P 616874-25-0P 616874-26-1P
616874-27-2P 616874-28-3P 616874-29-4P
616874-30-7P 616874-31-8P 616874-32-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furylspiro[1-azabicyclo[2.2.2]octane-furo[2,3-b]pyridine] derivs. as agonists of α7 nicotinic receptor for treatment or prophylaxis of psychotic disorders or intellectual impairment disorders)

RN 616874-03-4 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-benzofuranyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-04-5 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-bromo-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-06-7 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-2-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-07-8 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-2-furanyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616874-09-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-3-furanyl)-, dihydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 616874-11-4 CAPLUS
CN 2-Furancarboxaldehyde, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-13-6 CAPLUS
CN 2-Furanmethanol, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-14-7 CAPLUS
CN 2-Furancarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-15-8 CAPLUS

CN 2-Furancarbonitrile, 5-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-16-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-benzofuranyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-18-1 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-fluoro-3-benzofuranyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-19-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-2-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-20-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-methyl-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-21-6 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-fluoro-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-23-8 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-24-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-bromo-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-25-0 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[5-(trifluoromethyl)-3-furanyl]-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-26-1 CAPLUS
CN 2-Furanmethanamine, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-27-2 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-2-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-28-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-bromo-2-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-29-4 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[5-(trifluoromethyl)-2-furanyl]-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-30-7 CAPLUS
CN 2-Furanmethanamine, 5-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-31-8 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(4,5-dimethyl-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616874-32-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(4,5-dimethyl-2-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 477727-60-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of furylspiro[1-azabicyclo[2.2.2]octane-furo[2,3-b]pyridine] derivs. as agonists of α7 nicotinic receptor for treatment or prophylaxis of psychotic disorders or intellectual impairment disorders)
RN 477727-60-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AB The invention discloses a method for treating fibromyalgia syndrome and fibromyalgia-related symptoms with an agonist of α7 nicotinic acetylcholine receptors.
AN 2003:319637 CAPLUS
DN 138:314632
TI Agonists of α7 nicotinic acetylcholine receptors for the treatment of fibromyalgia syndrome
IN McCarthy, Dennis; Gurley, David
PA AstraZeneca AB, Swed.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032897	A2	20030424	WO 2002-SE1887	20021015
	WO 2003032897	A3	20031113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1453828 A2 20040908 EP 2002-778156 20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005510482 T2 20050421 JP 2003-535703 20021015
US 2004259909 A1 20041223 US 2004-492891 20040416
PRAI SE 2001-3463 A 20011016
SE 2002-1033 A 20020404
WO 2002-SE1887 W 20021015
OS MARPAT 138:314632
IT 220100-24-3 220100-24-3D, enantiomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α7 nicotinic agonists for treatment of fibromyalgia syndrome)
RN 220100-24-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 220100-24-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-furanyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AB Title compound (I) was prepared Thus, (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine, 3-furylboronic acid, (PPh3)4Pd, and Na2CO3 were heated in H2O/THF/EtOH at 70° for 24h to give I. I showed acetylcholine α7 receptor binding with Ki = 0.033 nM.
AN 2003:58809 CAPLUS
DN 138:106681
TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine as a nicotinic acetylcholine receptor ligand
IN Eifion, Phillips
PA USA
SO U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S. Ser. No. 871,773,

abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003018042	A1	20030123	US 2002-159786	20020531
	US 6569865	B2	20030527		
PRAI	US 2001-367351P	P	20010601		
	US 2001-871773	B1	20010601		

IT 477727-60-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furanylspiroazabicyclooctanefuro]pyridine as a nicotinic acetylcholine receptor ligand)
RN 477727-60-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The title compound I.2HCl, useful in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders (no biol. data given), was prepared by bromination of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] followed by reacting the resulting 5'-bromo derivative with 3-furylboronic acid in the presence of Pd(PPh3)4 and Na2CO3 in H2O/EtOH/THF.
AN 2002:927434 CAPLUS
DN 138:14045
TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic acetylcholine receptors
IN Phillips, Eifion
PA Astrazeneca Ab, Swed.

SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096912	A1	20021205	WO 2002-SE1031	20020529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2455341	AA	20021205	CA 2002-2455341	20020529
EP 1397366	A1	20040317	EP 2002-731063	20020529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1512995	A	20040714	CN 2002-811049	20020529
BR 2002010075	A	20040817	BR 2002-10075	20020529
JP 2004532877	T2	20041028	JP 2003-500091	20020529
NZ 529426	A	20050729	NZ 2002-529426	20020529
ZA 2003008779	A	20050211	ZA 2003-8779	20031111
PRAI US 2001-295206P	P	20010601		
WO 2002-SE1031	W	20020529		

IT 477727-59-6P 477727-60-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic acetylcholine receptors)
RN 477727-59-6 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 477727-60-9 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(3-furanyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
GI



II

AB RNR1R2 [R = spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine]-5- or -6-yl][I; R1 = (hetero)aryl(alkyl), CH2CH:CHR3, CH2C.tplbond.CR3; R2 = H, alkyl, CHO, alkanoyl, alkoxycarbonyl, etc.; R3 = (hetero)aryl(alkyl)] were prepared Thus, quinuclidin-3-one underwent methylene insertion with Me3S(O)I and the N-BH3-complexed epoxide condensed with 2-chloropyridine to give, in 3 addnl. steps, (S)- and (R)-RH the latter of which was converted in 3 addnl. steps to title compound (R)-II. Data for biol. activity of I were given.
AN 2000:493546 CAPLUS
DN 133:120318
TI Preparation of furopyridineamines as nicotinic receptor agonists
IN Loch, James, III; Mullen, George; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042044	A1	20000720	WO 1999-SE2478	19991223
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359990	AA	20000720	CA 1999-2359990	19991223
	EP 1147114	A1	20011024	EP 1999-967044	19991223
	EP 1147114	B1	20030521		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO				
	BR 9916906	A	20011030	BR 1999-16906	19991223
	TR 200102042	T2	20020521	TR 2001-200102042	19991223
	EE 200100370	A	20021015	EE 2001-370	19991223
	EE 4528	B1	20050815		
	JP 2002534525	T2	20021015	JP 2000-593611	19991223
	AT 240960	E	20030615	AT 1999-967044	19991223
	NZ 512733	A	20030829	NZ 1999-512733	19991223
	PT 1147114	T	20031031	PT 1999-967044	19991223
	CN 1132837	B	20031231	CN 1999-816422	19991223
	ES 2200590	T3	20040301	ES 1999-967044	19991223
	RU 2233282	C2	20040727	RU 2001-122812	19991223
	AU 775433	B2	20040729	AU 2000-23343	19991223
	TW 227237	B1	20050201	TW 2000-89100989	20000121
	US 2003149065	A1	20030807	US 2000-529654	20000418
	US 6995167	B2	20060207		
	ZA 2001005527	A	20021004	ZA 2001-5527	20010704
	NO 2001003478	A	20010914	NO 2001-3478	20010713
	HK 1040517	A1	20030905	HK 2002-102161	20020321
	US 2005250802	A1	20051110	US 2005-181098	20050714
PRAI	SE 1999-100	A	19990115		
	WO 1999-SE2478	W	19991223		
	US 2000-529654	A3	20000418		

OS MARPAT 133:120318

IT 284486-11-9P 284486-12-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furopyridineamines as nicotinic receptor agonists)

RN 284486-11-9 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine, N-(2-furanylmethyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 284486-12-0 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine, N-(3-furanylmethyl)-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I



II

AB Title compds. (I; A = N or CR2; D = N or CR4; G = N or CR3; R2-R4 = H, halo, alkyl, alkoxy, etc.; W = O, H2, F2; X = O or S; Y = CH, N, NO; each Z, independently, may be bond or CH2) were prepared Thus, 3-quinuclidinone was cyclocondensed with Me3S(O)I and the N-BH3-complexed product condensed with 2-chloropyridine to give, after cyclization and decomplexation, title compound II.

AN 1999:77567 CAPLUS

DN 130:139332

TI Preparation of spiro[azabicyclo-furopyridine] derivatives and analogs as α7 nicotinic receptor agonists

IN Phillips, Eifion; Mack, Robert; Macor, John; Semus, Simon

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9903859	A1	19990128	WO 1998-SE1364	19980710
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9805995	A	19990803	ZA 1998-5995	19980707
	CA 2296031	AA	19990128	CA 1998-2296031	19980710
	AU 9883679	A1	19990210	AU 1998-83679	19980710
	AU 739022	B2	20011004		
	EP 996622	A1	20000503	EP 1998-934078	19980710
	EP 996622	B1	20021009		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000129	T2	20000721	TR 2000-200000129	19980710
	BR 9810924	A	20000815	BR 1998-10924	19980710
	EE 200000031	A	20001016	EE 2000-31	19980710
	EE 4399	B1	20041215		
	JP 2001510194	T2	20010731	JP 2000-503083	19980710

	NZ 502298	A	20020201	NZ 1998-502298	19980710
	EP 1213291	A1	20020612	EP 2002-5982	19980710
	EP 1213291	B1	20041201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	AT 225792	E	20021015	AT 1998-934078	19980710
	PT 996622	T	20030131	PT 1998-934078	19980710
	ES 2185185	T3	20030416	ES 1998-934078	19980710
	RU 2202553	C2	20030420	RU 2000-103958	19980710
	SK 283484	B6	20030805	SK 1999-1835	19980710
	CN 1117755	B	20030813	CN 1998-809055	19980710
	AT 283859	E	20041215	AT 2002-5982	19980710
	ES 2231599	T3	20050516	ES 2002-5982	19980710
	TW 515799	B	20030101	TW 1998-87111679	19980717
	US 6110914	A	20000829	US 1998-171983	19981029
	NO 2000000226	A	20000314	NO 2000-226	20000117
	US 6369224	B1	20020409	US 2000-594703	20000616
	HK 1025322	A1	20030425	HK 2000-104490	20000720
	HK 1031382	A1	20040227	HK 2001-102261	20010328
	US 2002187994	A1	20021212	US 2002-93939	20020308
	US 6703502	B2	20040309		
	HK 1046274	A1	20050520	HK 2002-107504	20021016
	US 2003166935	A1	20030904	US 2003-396215	20030324
	US 6706878	B2	20040316		
	US 2005004099	A1	20050106	US 2004-801085	20040315
PRAI	SE 1997-2746	A	19970718		
	SE 1998-977	A	19980324		
	EP 1998-934078	A3	19980710		
	WO 1998-SE1364	W	19980710		
	US 1998-171983	A3	19981029		
	US 2000-594703	A1	20000616		
	US 2002-93939	A3	20020308		
	US 2003-396215	A3	20030324		

OS MARPAT 130:139332

IT 220100-24-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro[azabicyclo-furopyridine] derivs. and analogs as α7 nicotinic receptor agonists)

RN 220100-24-3 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-furanyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT